Does rituximab cause hair loss? This is a common concern for patients starting this monoclonal antibody therapy. Rituximab targets CD20 proteins on B-lymphocytes and is used to treat conditions including B-cell non-Hodgkin lymphoma, chronic lymphocytic leukaemia, and rheumatoid arthritis. Unlike conventional chemotherapy, rituximab does not directly attack rapidly dividing cells such as hair follicles, meaning hair loss is not a pharmacologically expected side effect of rituximab monotherapy. However, when used in combination regimens such as R-CHOP, hair loss may occur due to the accompanying cytotoxic agents.

Does Rituximab Cause Hair Loss?

Rituximab monotherapy does not typically cause hair loss, as hair follicles lack the CD20 target; alopecia is not listed as a common side effect in the UK SmPC for rituximab alone.

Experiencing these side effects? Our pharmacists can help you navigate them →

Rituximab is a monoclonal antibody used to treat a range of conditions, including certain B-cell non-Hodgkin lymphomas, chronic lymphocytic leukaemia (CLL), rheumatoid arthritis, granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA). It works by targeting the CD20 protein found on the surface of B-lymphocytes, leading to their elimination through complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis. This targeted mechanism distinguishes rituximab from conventional chemotherapy agents, which tend to affect all rapidly dividing cells — including those in hair follicles.

Hair loss (alopecia) is not typically associated with rituximab monotherapy. The Summary of Product Characteristics (SmPC) for UK-licensed rituximab products (such as MabThera and its biosimilars, available via the MHRA/electronic Medicines Compendium) does not list alopecia as a common adverse effect of rituximab used alone. Because hair follicle cells do not express CD20, they are not directly targeted by rituximab, and the classic chemotherapy-induced hair loss pattern is not a pharmacologically expected consequence of its use.

However, when rituximab is used as part of combination chemotherapy regimens — for example, R-CHOP for lymphoma — the SmPC does list alopecia as a very common adverse effect of the regimen as a whole. In this context, hair loss is largely attributable to the cytotoxic agents (such as cyclophosphamide and doxorubicin) rather than to rituximab itself. In these cases, it can be difficult to attribute hair changes specifically to rituximab rather than to the accompanying drugs.

Patients who experience hair thinning or shedding whilst receiving rituximab as a standalone therapy should discuss this with their clinical team, as there is no well-established direct causal link, and other contributing factors may need to be explored. If you suspect rituximab or any other medicine is causing a side effect, you can report this via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

How Common Is Hair Loss With Rituximab?

Hair loss is not considered a common or expected side effect of rituximab monotherapy; rare post-marketing case reports exist but causality has not been firmly established.

Not sure if this is normal? Chat with one of our pharmacists →

Based on current clinical evidence and UK prescribing information, hair loss is not considered a common or expected side effect of rituximab monotherapy. In large clinical trials and post-marketing surveillance data reviewed by regulatory bodies including the EMA and MHRA, alopecia does not feature prominently among the adverse effects reported by patients receiving rituximab alone. The EMA European Public Assessment Report (EPAR) for rituximab supports this position.

That said, individual patient experiences can vary. There are rare post-marketing case reports of hair changes occurring in patients receiving rituximab; however, causality has not been firmly established in these instances. It is also important to note that the underlying conditions for which rituximab is prescribed can themselves cause hair thinning as a disease manifestation. For example, rheumatoid arthritis and systemic lupus erythematosus (SLE) — noting that rituximab use in SLE is generally off-label in the UK and is typically reserved for specialist settings — are both associated with hair changes that may be mistakenly attributed to the medication.

Additionally, factors such as nutritional deficiencies, stress related to illness, hormonal changes, and concurrent medications can all contribute to hair loss independently of rituximab. When rituximab is used alongside other immunosuppressants or chemotherapy agents, the cumulative effect on hair follicles may be more pronounced. Clinicians and patients should therefore consider the full treatment context when evaluating hair changes:

• Rituximab monotherapy: Alopecia not commonly reported; rare post-marketing reports exist with uncertain causality

• Combination chemotherapy (e.g., R-CHOP): Alopecia listed as very common in the SmPC; largely attributable to cytotoxic agents

• Autoimmune disease context: Underlying condition may itself cause hair thinning

• Concurrent medications: Other drugs in the regimen should be reviewed

Overall, the available evidence suggests that rituximab itself is unlikely to be a primary driver of significant hair loss.

Why Some Treatments Affect Hair Growth

Conventional chemotherapy causes hair loss by disrupting rapidly dividing follicle cells during the anagen phase; rituximab does not target follicle cells and so does not cause this effect directly.

To understand why rituximab is less likely to cause hair loss than conventional chemotherapy, it helps to consider how different treatments interact with the body's cells. Hair follicles are among the most metabolically active structures in the human body, cycling through phases of active growth (anagen), transition (catagen), and rest (telogen). Treatments that disrupt rapidly dividing cells — such as cytotoxic chemotherapy — interfere with the anagen phase, causing the characteristic diffuse hair loss known as anagen effluvium, which typically begins two to four weeks after starting treatment.

Rituximab, by contrast, is a targeted biological therapy. Its mechanism of action is highly specific: it binds to CD20 antigens on B-cells and triggers their elimination. Because hair follicle cells do not express CD20, they are not directly targeted by rituximab, which explains why hair loss is not a pharmacologically expected consequence of its use.

A separate phenomenon known as telogen effluvium — where physiological or psychological stress causes a large proportion of hairs to enter the resting phase simultaneously — can occur in patients with serious illness, following surgery, or during periods of significant immune system disruption. This type of hair shedding is diffuse, typically temporary, and usually becomes apparent two to three months after the triggering event. It may be observed in patients undergoing treatment for conditions such as lymphoma or autoimmune disease, regardless of the specific agent used.

Nutritional deficiencies can also contribute to hair thinning. The strongest evidence in routine clinical practice relates to iron deficiency and thyroid dysfunction; zinc and vitamin D deficiencies may also play a role in some individuals, though the evidence for these is more associative. These factors should be considered as part of a holistic assessment, particularly in patients with prolonged illness or restricted dietary intake.

Managing Hair Changes During Rituximab Treatment

Gentle hair care, adequate nutrition, and blood tests to exclude reversible causes such as iron deficiency or thyroid dysfunction are the recommended first steps for managing hair changes during treatment.

If you notice changes to your hair whilst receiving rituximab — whether as a standalone treatment or as part of a combination regimen — there are several practical steps that may help to minimise distress and support hair health during this period.

General hair care advice:

• Use gentle, sulphate-free shampoos and avoid excessive heat styling

• Avoid tight hairstyles that place tension on the scalp

• Pat hair dry rather than rubbing vigorously with a towel

• Consider a soft-bristle brush to reduce mechanical breakage

From a nutritional standpoint, ensuring adequate intake of protein and key micronutrients supports overall hair follicle health. If you have concerns about your diet or suspect a deficiency, your GP or specialist can arrange appropriate blood tests; a dietitian can then advise on nutrition based on the results. First-line investigations in UK practice typically include thyroid function (TSH), full blood count (FBC), and ferritin; zinc and vitamin D may be checked where clinically indicated based on your history and local protocols.

NICE has published guidance on the diagnosis and management of alopecia areata (refer to the current NICE guideline on alopecia areata for the up-to-date guideline number and recommendations), which highlights the importance of identifying and addressing reversible contributing factors before initiating specific treatments.

For patients receiving rituximab as part of a chemotherapy regimen where hair loss is expected, NHS cancer services often provide access to a wig service on the NHS, as well as support from specialist oncology nurses and allied health professionals. Scalp cooling (cold cap therapy) is used in some UK centres to reduce hair loss during certain chemotherapy regimens; however, it is generally used for solid tumour chemotherapy and is usually not recommended for haematological cancers such as lymphoma or leukaemia. Whether scalp cooling is suitable for you depends on your specific treatment protocol and local centre policy — discuss this with your oncology team. Macmillan Cancer Support provides detailed, up-to-date information on scalp cooling and NHS wig services.

Emotional support is equally important. Hair changes, even temporary ones, can significantly affect self-image and wellbeing. Charities such as Macmillan Cancer Support and Alopecia UK offer practical resources and peer support for those experiencing treatment-related hair changes.

When to Speak to Your NHS Care Team

Contact your NHS care team promptly if you notice sudden, patchy, or significant hair shedding, or if hair loss is accompanied by other new symptoms such as fatigue or skin changes.

Whilst hair loss is not a commonly expected side effect of rituximab, any new or concerning symptom during treatment should be discussed with your NHS care team promptly. Open communication with your consultant, specialist nurse, or GP ensures that any changes are properly evaluated and that other potential causes are not overlooked.

You should contact your care team if you notice:

• Sudden or significant hair shedding that concerns you

• Patchy hair loss, which may suggest alopecia areata — an autoimmune condition that can occasionally be associated with immune-modulating therapies

• Hair loss accompanied by other new symptoms such as fatigue, weight changes, or skin changes, which may indicate a thyroid or other systemic issue

• Scalp irritation, redness, soreness, or scaling

• Emotional distress related to changes in your appearance

Your care team can arrange relevant investigations to identify any treatable underlying causes. In UK primary care and specialist practice, first-line blood tests typically include thyroid function (TSH), full blood count (FBC), and ferritin (iron stores). Further tests — such as B12, folate, zinc, or vitamin D — may be considered based on your individual history, examination findings, and local guidance. If alopecia areata is suspected, or if there is diagnostic uncertainty or concern about scarring alopecia, a referral to a dermatologist may be appropriate. The current NICE guideline on alopecia areata provides a clear pathway for assessment and management.

It is also worth raising any concerns about hair loss at your routine treatment review appointments, even if the changes seem minor. Your clinical team is best placed to determine whether the hair changes are related to your medication, your underlying condition, or another factor entirely.

If you believe rituximab or any other medicine may be causing a side effect, you can report this to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app. This helps the MHRA monitor the safety of medicines used in the UK.

Never stop or adjust your rituximab treatment without medical advice, as doing so could have serious consequences for the condition being treated. The NHS is committed to supporting patients holistically throughout their treatment journey, and no concern is too small to raise.

Frequently Asked Questions